| HUMAN-TRIAL | evidence | Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial. | Tirzepatide | Lipid & cardiovascular markers · human-rct | 2026-02-01 |
| HUMAN-TRIAL | evidence | Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial. | Tirzepatide | Glycemic control · human-rct | 2026-01-01 |
| HUMAN-TRIAL | evidence | Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice. | Tirzepatide | Glycemic control · human-observational | 2026-01-01 |
| HUMAN-TRIAL | evidence | Weight loss in people with type 1 diabetes over 12 months: Real-world data comparing tirzepatide, semaglutide and liraglutide. | Tirzepatide | Glycemic control · human-observational · n = 250 | 2026-01-01 |
| HUMAN-TRIAL | evidence | Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial. | Tirzepatide | Weight & fat loss · human-rct | 2026-01-01 |
| HUMAN-TRIAL | evidence | GLP-1 agonist-associated presentations to unscheduled care: An opportunistic pilot study. | Tirzepatide | Glycemic control · human-observational | 2026-01-01 |
| HUMAN-TRIAL | evidence | Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies. | Tirzepatide | Glycemic control · human-rct | 2026-01-01 |
| HUMAN-TRIAL | evidence | People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment. | Tirzepatide | Weight & fat loss · human-rct · n = 3788 | 2026-01-01 |
| HUMAN-TRIAL | evidence | Gastrointestinal adverse events associated with tirzepatide: A bibliometric and pharmacovigilance analysis. | Tirzepatide | Gut barrier & GI healing · human-observational | 2026-01-01 |
| HUMAN-TRIAL | evidence | Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. | Tirzepatide | Glycemic control · human-observational | 2025-12-18 |
| HUMAN-TRIAL | evidence | GLP-1 receptor agonist utilization is associated with a low risk of Anesthesia-related complications prior to total joint arthroplasty. | Tirzepatide | Glycemic control · human-observational · n = 83 | 2025-12-06 |
| HUMAN-TRIAL | evidence | Short-term effects of low-dose tirzepatide on lipid profile, glucose homeostasis and hepatic steatosis index in adults with obesity, but without diabetes mellitus: a prospective observational study. | Tirzepatide | Weight & fat loss · human-observational | 2025-12-01 |
| HUMAN-TRIAL | evidence | Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight. | Tirzepatide | Sleep quality · human-rct | 2025-12-01 |
| HUMAN-TRIAL | evidence | Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide. | Tirzepatide | Glycemic control · human-rct | 2025-12-01 |
| HUMAN-TRIAL | evidence | Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial. | Tirzepatide | Glycemic control · human-rct | 2025-12-01 |
| HUMAN-TRIAL | evidence | Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. | Tirzepatide | Glycemic control · human-rct | 2025-12-01 |
| HUMAN-TRIAL | evidence | Risk of lower extremity complications with GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors in peripheral artery disease. | Tirzepatide | Glycemic control · human-observational | 2025-12-01 |
| HUMAN-TRIAL | evidence | Impact of Tirzepatide on diet-related quality of life and treatment satisfaction in people with type 2 diabetes mellitus: a retrospective cross-sectional study. | Tirzepatide | Glycemic control · human-observational | 2025-11-01 |
| HUMAN-TRIAL | evidence | In adults with obesity but without type 2 diabetes, tirzepatide increased weight loss at 72 wk compared with semaglutide. | Tirzepatide | human-rct | 2025-11-01 |
| HUMAN-TRIAL | evidence | Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes. | Tirzepatide | Glycemic control · human-observational | 2025-10-01 |
| HUMAN-TRIAL | evidence | Predictors of Initial and Sustained Glycemic and Weight Response to Tirzepatide: A Post Hoc Analysis of SURPASS-4. | LY3298176 | Glycemic control · human-rct | 2025-10-01 |
| HUMAN-TRIAL | evidence | Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis. | LY3298176 | human-rct | 2025-09-09 |
| HUMAN-TRIAL | evidence | Real-world insights into incretin-based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross-sectional study. | Mounjaro | Weight & fat loss · human-observational · n = 411 | 2025-09-01 |
| HUMAN-TRIAL | evidence | Tirzepatide Treatment and Associated Changes in beta-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial. | LY3298176 | Glycemic control · human-rct | 2025-09-01 |
| HUMAN-TRIAL | evidence | Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial. | LY3298176 | Weight & fat loss · human-rct | 2025-07-29 |
| HUMAN-TRIAL | evidence | Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024. | Mounjaro | Glycemic control · human-observational | 2025-07-24 |
| HUMAN-TRIAL | evidence | TikTok's take on adverse effects for glucagon-like peptide-1 and gastric inhibitory polypeptide receptor agonists. | Mounjaro | human-observational | 2025-07-01 |
| HUMAN-TRIAL | evidence | Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial. | LY3298176 | human-rct | 2025-05-13 |
| HUMAN-TRIAL | evidence | Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy. | LY3298176 | Weight & fat loss · human-rct | 2025-02-25 |
| HUMAN-TRIAL | evidence | From awareness to action: evolving endocrinologist practices in obesity treatment in Italy. | Tirzepatide | Weight & fat loss · human-observational · n = 424 | 2025-01-01 |
| HUMAN-TRIAL | evidence | Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program. | LY3298176 | Glycemic control · human-rct | 2024-06-01 |
| HUMAN-TRIAL | evidence | LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. | LY3298176 | Glycemic control · human-rct | 2018-12-01 |
| HUMAN-TRIAL | evidence | Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. | LY3298176 | Glycemic control · human-rct | 2018-11-17 |
| HUMAN-TRIAL | evidence | Anti-obesity Pharmacotherapy and Inflammation | Mounjaro | Weight & fat loss · human-observational · n = 30 | — |
| HUMAN-TRIAL | evidence | Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial | Tirzepatide | human-rct · n = 168 | — |
| HUMAN-TRIAL | evidence | Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study | Tirzepatide | Glycemic control · n = 30 | — |
| HUMAN-TRIAL | evidence | Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea | LY-3298176 | human-rct · n = 469 | — |
| HUMAN-TRIAL | evidence | Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF | Mounjaro | human-rct · n = 602 | — |
| HUMAN-TRIAL | evidence | A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes | LY-3298176 | human-rct · n = 54 | — |
| HUMAN-TRIAL | evidence | Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB) | Tirzepatide | Addiction & substance use · human-rct · n = 46 | — |
| HUMAN-TRIAL | evidence | Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity | Tirzepatide | Weight & fat loss · n = 20 | — |
| HUMAN-TRIAL | evidence | Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients | Tirzepatide | human-rct · n = 52 | — |
| HUMAN-TRIAL | evidence | Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity | Tirzepatide | Weight & fat loss · human-rct · n = 63 | — |
| HUMAN-TRIAL | evidence | Tirzepatide in Idiopathic Intracranial Hypertension Trial | Tirzepatide | human-rct · n = 60 | — |
| HUMAN-TRIAL | evidence | Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over | Tirzepatide | Weight & fat loss · human-rct · n = 204 | — |
| HUMAN-TRIAL | evidence | An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder | Tirzepatide | Weight & fat loss · n = 45 | — |
| HUMAN-TRIAL | evidence | Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial | Tirzepatide | human-rct · n = 60 | — |
| HUMAN-TRIAL | evidence | Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants | Tirzepatide | Glycemic control · human-rct · n = 148 | — |
| HUMAN-TRIAL | evidence | Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV | Tirzepatide | n = 12 | — |
| HUMAN-TRIAL | evidence | Effect of Tirzepatide on Markers of MASLD in Patients With Obesity | Mounjaro | Weight & fat loss · n = 8 | — |